Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin

Annals of Pharmacotherapy

Volumn 50, Issue 11, 2016, Pages 909-917

  DeCarolis, Douglas D ^a   Westanmo, Anders D ^a   Chen, Yi Chie ^b   Boese, Amanda L ^a   Walquist, Mary A ^a   Rector, Thomas S ^b  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

anticoagulants; anticoagulation; antivirals; cytochrome P 450 interactions; drug interactions; gastroenterology; hepatitis C; pharmacokinetics; therapeutic monitoring; warfarin

Indexed keywords

DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; WARFARIN; ANTICOAGULANT AGENT; ANTIVIRUS AGENT;

ADULT; ANTICOAGULANT THERAPY; ANTIVIRAL THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC HEPATITIS C; COHORT ANALYSIS; DOSE RESPONSE; DRUG SENSITIVITY; FEMALE; HEART ATRIUM ARRHYTHMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM; AGED; COMBINATION DRUG THERAPY; DRUG INTERACTION; HEPATITIS C;

AGED; ANTICOAGULANTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84990213383     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016660325     Document Type: Article

References (44)

1. Smith BD, Morgan RL, Beckett GA. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
2. Moyer VA, ; US Preventive Services Task Force. Screening for hepatitis C virus Infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.
3. Ufer M., Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227-1246.
4. Gage BF, Fihn SD, White RH., Management and dosing of warfarin therapy. Am J Med. 2000;109:481-488.
5. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, ; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, suppl):e44S-e88S.
6. Keating GM., Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75:675-685.
7. Kirby BJ, Symonds WT, Kearney BP, Mathias AA., Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677-690.
8. Kwo PY, Badshah MB., New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20:235-241.
9. Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM., Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet. 2016;55:275-295.
10. Soriano V, Labarga P, Barreiro P. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11:333-341.
11. Brayer SW, Reddy KR., Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert Rev Gastroenterol Hepatol. 2015;9:547-558.
12. ® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204671s002lbl.pdf. Accessed June 4, 2016.
13. ® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205834s007s008s009lbl.pdf. Accessed June 4, 2016.
14. ® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206619s009lbl.pdf. Accessed June 4, 2016.
15. US Department of Veterans Affairs, National Center for Veterans Analysis and Statistics. VA benefits and health care utilization. http://www.va.gov/vetdata/docs/pocketcards/fy2014q4.pdf. Accessed June 4, 2016.
16. US Department of Veterans Affairs. VA Informatics and Computing Infrastructure (VINCI). http://www.hsrd.research.va.gov/for_researchers/vinci/. Accessed June 4, 2016.
17. Martínez SM, Crespo G, Navasa M, Forns X., Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335.
18. Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E., Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther. 2003;74:215-221.
19. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J., Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992;116:901-904.
20. Doi SA. Pharmacodynamic optimization of warfarin therapy. Clin Pharmacol Ther. 1994;55:597-601.
21. Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H., Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost. 1999;81:396-399.
22. Loebstein R, Yonath H, Peleg D. Interindividual variability in sensitivity to warfarin: nature or nurture? Clin Pharmacol Ther. 2001;70:159-164.
23. Rahman M, BinEsmael TM, Payne N, Butchart EG., Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother. 2006;40:397-401.
24. White HD, Gruber M, Feyzi J. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239-245.
25. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
26. Cannegieter SC, Rosendaal FR, Wintzen AR. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
27. Palareti G, Legnani C, Cosmi B. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 2005:3:955-961.
28. Menon RM., Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20-29.
29. Badri P., Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2016;60:105-114.
30. ® (ritonavir): highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020945s040lbl.pdf. Accessed June 4, 2016.
31. Yeh RF, Gaver VE, Patterson KB. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52-60.
32. Morcos PN, Chang L, Kulkarni R. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. Eur J Clin Pharmacol. 2013;69:1939-1949.
33. Foisy MM, Yakiwchuk EM, Hughes CA., Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42:1048-1059.
34. Knoell KR, Young TM, Cousins ES., Potential interaction involving warfarin and ritonavir. Ann Pharmacother. 1998;32:1299-1302.
35. Bonora S, Lanzafame M, D’Avolio A. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis. 2008;46:146-147.
36. Hughes CA, Freitas A, Miedzinski LJ., Interaction between lopinavir/ritonavir and warfarin. CMAJ. 2007;177:357-359.
37. Anderson AM, Chane T, Patel M. Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. AIDS Patient Care STDS. 2012;26:454-462.
38. Rolan PE., Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37:125-128.
39. Benet LZ, Hoener BA., Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121.
40. Schulman S., Inhibition of warfarin activity by ribavirin. Ann Pharmacother. 2002;36:72-74.
41. Honda T, Toyoda H, Hayashi K. Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C. JAMA. 2005;293:1190-1192.
42. Yamamoto K, Honda T, Matsushita T, Kojima T, Takamatsu J., Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin. J Thromb Haemost. 2006;4:469-470.
43. Beste LA, Ioannou GN., Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev. 2015;37:131-143.
44. US Department of Veterans Affairs. VHA Directive 1033: Anticoagulation therapy management. http://www.va.gov/vhapublications/viewpublication.asp?pub_id=3129. Accessed July 5, 2016.